Business Information
The group's principal activity is to develop genetic diversity technologies, products and services for genetic biochemistry applications. The products include scoring single nucleotide polymorphism and microfluidics technologies. They are used in drug discovery, principally in the field of pharmacogenetics and dna synthesis. Genetic diversity information is used by the pharmaceutical and medical communities to facilitate the development of highly specific and efficacious drugs, to improve the effectiveness of existing drugs and to increase the likelihood of success of tissue transplants. The group's proprietary technologies are also used in other commercial applications outside the healthcare field including forensics, paternity testing, improved crop development and livestock breeding programs.
|
|
Name |
Title
|
Email
|
| George Poste | Chmn. | N/A | | Thomas Bologna | Dir., CEO, Pres. | N/A | | James Smith | CFO, VP | N/A | | Bruce Basarab | VP - North American Sales, Marketing | N/A | | James Beery | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 56,854 | (11,271) | | 2005 | 61,609 | (9,439) | | 2004 | 62,499 | (8,812)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
